The $35 Insulin Cap in 2026: Medicare, Commercial Plans, and Who Qualifies

Insulin is a life-sustaining medication for millions of Americans with type 1 and type 2 diabetes. Before the Inflation Reduction Act of 2022, Medicare Part D enrollees could pay hundreds of dollars per month for insulin depending on their plan's formulary tier and deductible status. The IRA changed that: starting January 1, 2023, all Medicare Part D plans must cap insulin out-of-pocket cost at $35 per one-month supply, and no deductible may apply to any covered insulin product. A parallel Part B provision capped insulin used in insulin pumps at $35 per month beginning July 1, 2023. For 2026, those caps remain in force and unchanged.

Three critical distinctions every insulin patient needs to understand in 2026. First, the $35 cap is a Medicare-only federal protection. Commercial employer plans and ACA Marketplace plans have no equivalent federal cap, though over 30 states have enacted their own insulin pricing laws for state-regulated plans. Second, the cap is per insulin product per month, not per fill or per vial. Third, the IRA cap covers all insulin types that a plan includes on its formulary: rapid-acting, short-acting, intermediate-acting, and long-acting formulations in both vial and pen form. If your Medicare plan covers an insulin, you pay no more than $35 for it in 2026, even before meeting your deductible. Patients who want to compare all Part D insulin costs can use the Medicare Plan Finder at medicare.gov.

Patients without Medicare coverage are not left without options in 2026. The three major insulin manufacturers all operate programs that cap or eliminate out-of-pocket insulin costs regardless of Medicare status. Eli Lilly's Insulin Value Program caps cost at $35 per month for any Lilly insulin with no income test required. Novo Nordisk's NovoCare Patient Assistance Program provides free insulin for patients whose household income is at or below 400 percent of the federal poverty level. Sanofi Patient Connection offers free insulin for income-qualified patients and a $35-per-month copay savings program for commercially-insured patients. For low-income patients who may qualify for Medicaid, insulin coverage is available in all 50 states with a nominal $1 to $4 copay. Check the federal poverty level eligibility requirements to see if you qualify for Medicaid or these manufacturer programs.

What Insulin $35 Cap Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same insulin $35 cap can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospital inpatient insulin billing operates entirely outside the $35 cap. When a patient is admitted to a hospital and requires insulin during their stay, the hospital bills insulin under Medicare Part A (inpatient) or as a facility charge under commercial insurance, not under Medicare Part D. The $35 per month Part D cap only applies to insulin dispensed at a pharmacy counter. During an inpatient stay, hospitals routinely bill insulin at $200 to $500 per dose or more, compared to the Medicare Part B Average Sales Price of approximately $12 per unit. That gap is a markup of 10 to 40 times the government's reference price.

Three structural factors drive inpatient insulin markup. First, hospitals purchase insulin at a negotiated acquisition cost but bill at a chargemaster rate that can be 10 to 40 times higher. Second, administration fees, nursing time, and sterile preparation charges are stacked on top of the drug charge itself. Third, insulin is dosed frequently (sometimes multiple times per day in intensive care), so even a modest per-dose markup compounds quickly over a multi-day admission. Patients who receive a hospital bill showing insulin charges above $200 per dose should request an itemized statement, identify the HCPCS J1815 or J1817 line item, and compare the billed amount to the 2026 Medicare ASP rate of roughly $12 per unit as a baseline for dispute.

Patients who are discharged from a hospital and need to fill an insulin prescription at a pharmacy for the first time are often surprised to find the cost significantly lower than what appeared on their inpatient bill. Part D protections and manufacturer savings programs apply at the pharmacy counter, not in the hospital. If you were charged hospital rates for insulin and want to dispute the markup, the CoveredUSA Medical Bill Analyzer can identify the specific line items and generate a dispute letter referencing the 2026 Medicare ASP benchmark.

HCPCS J-Codes: What Appears on Your Bill

When insulin is administered in a hospital or clinical setting, it appears on your bill under HCPCS Level II J-codes. These codes are public domain and let you identify and challenge inflated charges:

Patient Assistance Programs

Patients without Medicare, or commercially-insured patients without adequate state cap protections, have three major manufacturer programs that replicate or exceed the $35-per-month floor. None of the three programs requires Medicare eligibility. Retail cash-price insulin runs $72 to $300 per vial for analog formulations in 2026, so the savings from these programs are substantial. The key rule: manufacturer copay savings cards cannot be used with Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. section 1320a-7b). If you have any government insurance, use the income-based PAP track instead.

Medicare Part D Coverage for Insulin $35 Cap

Medicare Part D enrollees pay a maximum of $35 per month for every covered insulin product on their plan's formulary in 2026. The cap is mandated by the Inflation Reduction Act of 2022 (Public Law 117-169, signed August 16, 2022) and took effect January 1, 2023. The cap is not a discount or coupon: it is a statutory ceiling. No deductible applies to insulin under Part D in 2026. If your pharmacy charged you more than $35 in a calendar month for an insulin covered by your plan, that is a billing error and you should call your plan's member services number immediately. Starting in 2026, the plan calculates your cost as the lesser of: $35, 25 percent of the negotiated price, or 25 percent of the Maximum Fair Price if the insulin is subject to IRA price negotiation.

A separate $35 per month Medicare Part B cap applies to insulin used with insulin pumps that qualify as durable medical equipment, effective July 1, 2023. Part B insulin coverage is distinct from Part D: Part B covers only insulin delivered by a Medicare-covered pump, while Part D covers all other prescription insulin. For Part B, the standard 20 percent coinsurance and the $283 annual Part B deductible apply to the pump equipment and supplies, but the insulin itself is capped at $35 per month. Patients who use both a pump (Part B) and multiple daily injections (Part D) benefit from both caps.

Medicare Part D does not cover insulin used for weight loss or any off-label purpose. All insulin covered under Part D must be for the treatment of diabetes. The $35 cap applies only to the insulins your specific plan covers; if a preferred insulin is not on your plan's formulary, ask your prescriber to submit a formulary exception request. CMS data shows that approximately 3.3 million Medicare Part D enrollees use insulin, and all of them benefit from this cap in 2026. Patients with very low income may also qualify for Medicare Extra Help, which can further reduce Part D costs on other medications to near zero.

Common Insulin $35 Cap Billing Errors

If you have Medicare Part D and paid more than $35 per month for insulin, or received a hospital bill with insulin charges over $200 per dose, check for these common errors before paying:

• Deductible applied to insulin at a Part D pharmacy: the IRA cap removes the deductible for insulin. If your plan charged you the deductible amount before applying the $35 cap, request a billing correction and refund from your plan.
• Manufacturer savings card applied to a Medicare claim: federal law bars manufacturer copay cards from Medicare, Medicaid, TRICARE, and VA claims. If a pharmacy applied a savings card to a Medicare claim, the claim may be reversed, leaving you responsible for the balance. The correct path for Medicare patients is the income-based manufacturer PAP, not the savings card.
• Wrong insulin dispensed and billed at a higher-tier copay: if your plan substituted a formulary insulin without your prescriber's agreement, you may be entitled to a tier exception to pay the lower-tier amount. Request a formulary exception or step-therapy override.
• Hospital inpatient insulin billed at $200+ per dose: inpatient insulin is not covered by the $35 Part D cap. However, charges above $100 per vial equivalent (far above the $12 Medicare ASP rate) are common dispute targets. Request an itemized bill with J-codes, then contact the hospital's billing department to request a reduction to the Medicare rate.
• Insulin pump insulin billed under Part D instead of Part B: if you use a Medicare-covered insulin pump, your pump insulin should be billed under Part B (with the $35 cap), not Part D. Getting it billed under the wrong part can result in higher cost-sharing. Ask your durable medical equipment supplier which benefit is being billed.
• Commercial plan applying a deductible to insulin in a state with a copay cap law: if you live in California, Colorado, Illinois, New Jersey, New York, or Connecticut (among others), your state-regulated commercial plan may be required to cap insulin without applying a deductible. Check your state's insurance commissioner website to see if your plan type is covered by your state's insulin cap law. Note: ERISA self-funded employer plans are exempt from state insurance laws.

Frequently Asked Questions